Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAISE-BP: Mirabegron in POTS
NCT06133075Phase 2Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Dec 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mirabegron in postural orthostatic tachycardia syndrome (POTS), syncope, orthostatic intolerance, sponsored by Cedars-Sinai Medical Center. Started Dec 2023; status: completed.
02
Drugs
mirabegron
03
Conditions
postural orthostatic tachycardia syndrome (POTS)syncopeorthostatic intolerance
Beyond the preview
Go deeper on NCT06133075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06133075.